Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine - PubMed (original) (raw)

Review

Paul L Durham. Headache. 2008 Sep.

Abstract

The neuropeptide calcitonin gene-related peptide (CGRP) is implicated in the underlying pathology of migraine. Serum levels of CGRP, which are elevated during a migraine attack, have been reported to return to normal with alleviation of pain. In addition, CGRP administration has been shown to cause a migraine-like headache in susceptible individuals. Importantly, CGRP receptors are found on many cell types within the trigeminovascular system that are thought to play important roles in controlling inflammatory and nociceptive processes. Based on these findings, it was proposed that blockage of CGRP receptor function and, hence, the physiological effects of CGRP would be effective in aborting a migraine attack. This review will summarize key preclinical data that support the therapeutic potential of using CGRP receptor antagonists or molecules that bind CGRP within the context of current neurovascular theories on migraine pathology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Durham has received grant support from Capnia, Colucid, Glaxo Smith Kline, MAP Pharmaceuticals, Merck, and Minster Pharmaceuticals.

Figures

Figure

Figure

Schematic of a single trigeminal ganglion neuron and associated satellite glial cells. Calcitonin gene-related peptide that is synthesized in the neuronal cell body can be released from the cell body or from peripheral or central terminals following axonal transport.

Similar articles

Cited by

References

    1. Lipton R, Stewart W, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001;41:646–657. - PubMed
    1. Stewart W, Lipton R, Celentano D, Reed M. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1991;267:64–69. - PubMed
    1. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4:386–398. - PubMed
    1. Goadsby P, Lipton R, Ferrari M. Migraine – current understanding and treatment. N Engl J Med. 2002;346:257–270. - PubMed
    1. Dodick D, Silberstein S. Central sensitization theory of migraine: Clinical implications. Headache. 2006;46:S182–191. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources